Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|April 1, 2005
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-04-01-2005
- Volume 17
- Issue 4
Nanostructured Lipid Carriers: A Novel Generation of Solid Lipid Drug Carriers
Nanostructured lipid carriers are a new type of delivery system offering improved performance in terms of drug loading and long-term stability with the ability to form highly concentrated dispersions...
Advertisement
Articles in this issue
over 21 years ago
Nanotechnology Applications for Drug Deliveryover 21 years ago
Nanotech Not Big Enough for Pharma?over 21 years ago
Protecting Intellectual Property Prior to Commercializationover 21 years ago
Ion Exchange Resinates — The Technology Behind the Mysteryover 21 years ago
Maintaining the Safety of EU Drugsover 21 years ago
Defining The BordersAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement